Skip to main content

Table 5 Extracorporeal liver support therapy in primary vs. secondary (cardiac surgery) liver failure

From: Extracorporeal liver support: trending epidemiology and mortality - a nationwide database analysis 2007–2015

  2007 2008 2009 2010 2011 2012 2013 2014 2015 2007–2015
Overall ELS therapies, n 314 311 390 377 287 270 255 294 388 2886
Mortality (%) 57.32 55.63 46.41 46.42 52.61 55.18 61.18 50.00 44.84 51,49
Primary ALS, n (% of all ELS) 152 (48.41) 156 (50.16) 182 (46.67) 189 (50.13) 132 (45.99) 97 (35.93) 102(40.00) 92 (31.29) 131 (33.76) 1233 (42.72)
Mortality (%) 48,03 42,95 32,42 30,16 36,36 44,33 55,88 42,39 44,27 40,63
Secondary ALS, n (% of all ELS) 115 (36,62) 129 (41,48) 126 (32,31) 139 (36,87) 121 (42,16) 157 (58,15) 140 (54,90) 190 (64,63) 196 (50,52) 1313 (45,50)
Mortality (%) 80,00 75,19 69,84 62,59 77,69 64,97 69,29 54,74 69,90 68,39
  1. Data given as absolute numbers and percentage values of all ELS cases of the respective year. ELS, extracorporeal liver support; n, number. Further differentiation (age, sex) was not permitted in this subgroup analysis due to national data protection laws. For definitions of primary and secondary liver failure see text & Table 2